Cellular Epigenetic Reprogramming Clinic Model
Underwrite clinical infusion centers delivering Yamanaka factor (OSK) partial epigenetic reprogramming therapies to reverse cellular age and restore tissue function. Model annual patient therapeutic programs ($38,000/patient), and 15-yr IRR.
1. Capacity & Unit Economics
2. Financial Returns & Yield
OSK CELLULAR REJUVENATIONAnnual Net EBITDA
$0 / yr
15-Yr Project IRR
0.0%
Gross Revenue
$0 / yr
Total CapEx
$0
Annual OpEx
$0 / yr